MIAMI, Fla.—Russ Trenary, a long time ophthalmology executive, has been named president and CEO of InnFocus, Inc., LLC, a privately held medical device company with biomaterials expertise that has developed a patented micro-shunt for treating glaucoma.

The Company's main product, called the InnFocus MicroShunt, “has demonstrated several years of excellent performance in minimally-invasive glaucoma surgery outside of the United States,” an announcement said. Company founder Leonard Pinchuk, Ph.D., will remain with InnFocus to develop its product pipeline.

Trenary has spent over 30 years with ophthalmic medical device companies, including Allergan Inc. and Advanced Medical Optics.

The device is cleared by the U.S Food and Drug Administration to begin Phase 1 clinical trials. The company has raised $13.4 million thus far in a Series B financing led by the Hoya Group and its Surgical business. InnFocus is in the process of finishing the Series B offering to raise an additional $3 million. The funds will be used to complete the Phase 1 clinical trials, expand clinical studies in Europe where the device is CE Mark Approved, and to invest in the company's anticipated growth, the statement said.

Said Trenary, “We are eager to complete the Phase 1 FDA trials, and continue work outside of the United States to establish the InnFocus MicroShunt as the premier offering in the minimally-invasive glaucoma arena."

"We are at the perfect juncture in our company's history to bring in an accomplished, experienced veteran like Russ Trenary," said company founder Len Pinchuk, "His demonstrated leadership in developing and launching ophthalmic devices and his broad network of relationships with leading eye surgeons are a perfect blend. We look forward to having him guide us through the FDA and overseas clinical processes."

The InnFocus MicroShunt was developed in collaboration with the University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute.